Key Benefits

• Confirm the inflammation driving your asthma to tailor treatment.
• Spot type 2 airway inflammation; high eosinophils signal steroid and biologic benefit.
• Clarify flare versus infection; low CRP supports noninfectious flare, high CRP flags infection.
• Guide therapy selection; higher eosinophils predict stronger response to inhaled steroids.
• Flag exacerbation risk; elevated eosinophils link to more frequent attacks.
• Track control and response; falling eosinophils show improvement after anti-inflammatory treatment.
• Identify other issues; raised CRP prompts evaluation for infection or systemic inflammation.
• Interpret results with spirometry, FeNO, and your symptoms for full context.

What are Asthma Biomarkers?

Asthma biomarkers are measurable signals from blood, breath, or airway secretions that reveal the kind and intensity of inflammation driving your symptoms. They help identify the dominant immune pathway—most often type 2 inflammation (T2) involving allergy-related cells and messengers—and distinguish it from other patterns. Key examples include markers of eosinophilic activity (eosinophils), airway gas produced during inflammation (exhaled nitric oxide, FeNO), allergy signals (total and specific IgE), and proteins released by stressed airway tissue (periostin). Together, these markers show how inflamed and reactive the airways are (airway hyperresponsiveness), how likely flare-ups are, and how well current treatment is controlling disease activity. Clinically, they reduce guesswork: guiding the choice and intensity of inhaled anti-inflammatory therapy, flagging when biologic medicines targeting IL‑5 or IL‑4/IL‑13 pathways may help, and tracking response over time. In short, asthma biomarkers translate the biology of your airways into actionable information for personalized, more effective care.

Why are Asthma biomarkers important?

Asthma biomarkers are measurable signs of airway and immune activity that reveal what kind of inflammation is driving symptoms, how active it is today, and how it may affect the lungs and the rest of the body. They connect the respiratory tract to the immune, vascular, and metabolic systems, helping explain flares, future risk, and response patterns over time.

Eosinophils reflect type 2 (allergic) airway inflammation; a common reference for absolute eosinophils is about 0–500, with “healthier” control often seen toward the lower–middle part of that range. C‑reactive protein (CRP) mirrors whole‑body inflammation; values below about 1 are low, 1–3 average, and above 3 high, with optimal risk generally near the low end.

When eosinophils and CRP sit low, physiology points to minimal allergic and systemic inflammation. Asthma may still cause cough, chest tightness, or exercise‑induced wheeze, but symptoms are less driven by eosinophilic swelling and mucus. Children can show low eosinophils even with episodic viral‑triggered wheeze, and in pregnancy, lower eosinophils can reflect immune shift without excluding asthma activity.

Higher eosinophils indicate active eosinophilic airway inflammation—more mucus, nighttime symptoms, and a higher chance of sudden exacerbations. Marked CRP elevation signals broader systemic inflammation that can amplify airway irritability and fatigue; in adults, persistently high CRP also tracks with cardiovascular risk. Teens with atopy often show eosinophil‑skewed patterns during allergy seasons.

Big picture: these biomarkers map the dialogue between lungs, immune circuits, and vascular health. Keeping eosinophils and CRP in favorable ranges aligns with quieter airways, fewer flares, less airway remodeling over years, and lower systemic risk—linking day‑to‑day breathing to long‑term respiratory and cardiometabolic outcomes.

What Insights Will I Get?

Asthma biomarker testing matters because airway inflammation doesn’t stay local—it influences oxygen delivery, energy, sleep quality, cognition, and cardiometabolic strain through immune signaling. Tracking inflammatory tone helps gauge airway stability and systemic spillover. At Superpower, we test these specific biomarkers: Eosinophils, CRP.

Eosinophils are white blood cells that drive type 2 (allergic/eosinophilic) inflammation. In asthma, higher blood eosinophils often mirror eosinophilic activity in the airways and correlate with variable airflow and exacerbation risk. C‑reactive protein (CRP) is an acute‑phase protein made by the liver that reflects whole‑body inflammation. In asthma, CRP can rise during exacerbations or with coexisting inflammatory stress (e.g., infection), but it is not specific to the lungs.

For stability and healthy function, eosinophils within typical reference ranges suggest quieter type 2 airway activity and a more predictable bronchial environment. Persistently elevated eosinophils point to ongoing eosinophilic inflammation, mucus hypersecretion, and a higher likelihood of swings in symptoms. A low CRP indicates a low systemic inflammatory burden that supports steadier respiratory control. Elevated CRP signals broader inflammatory activation that can amplify airway hyperreactivity or indicate concurrent illness, warranting interpretation alongside symptoms and other data.

Notes: Interpretation is influenced by recent infections, allergen exposure, and parasitic disease (raise eosinophils); corticosteroids (lower eosinophils and CRP); smoking and adiposity (raise CRP); age and pregnancy (shift leukocyte distributions); circadian timing and recent strenuous exercise (transient changes); and assay/lab reference variability.